Long-term control of recurrent or refractory viral infections after allogeneic HSCT with third-party virus-specific T cells.
Withers B, Blyth E, Clancy LE, Yong A, Fraser C, Burgess J, Simms R, Brown R, Kliman D, Dubosq MC, Bishop D, Sutrave G, Ma CKK, Shaw PJ, Micklethwaite KP, Gottlieb DJ.
Withers B, et al. Among authors: yong a.
Blood Adv. 2017 Nov 2;1(24):2193-2205. doi: 10.1182/bloodadvances.2017010223. eCollection 2017 Nov 14.
Blood Adv. 2017.
PMID: 29296867
Free PMC article.